Folgen
Paul de Souza
Paul de Souza
Sydney University, Western Sydney University
Bestätigte E-Mail-Adresse bei sydney.edu.au
Titel
Zitiert von
Zitiert von
Jahr
Abiraterone in metastatic prostate cancer without previous chemotherapy
CJ Ryan, MR Smith, JS De Bono, A Molina, CJ Logothetis, P De Souza, ...
New England Journal of Medicine 368 (2), 138-148, 2013
32102013
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
RJ Motzer, TE Hutson, D Cella, J Reeves, R Hawkins, J Guo, P Nathan, ...
New England Journal of Medicine 369 (8), 722-731, 2013
20902013
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall …
CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ...
The Lancet Oncology 16 (2), 152-160, 2015
15512015
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
JAMA Oncology 6 (7), 1003-1010, 2020
10002020
Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized …
LS Rosen, D Gordon, NS Tchekmedyian, R Yanagihara, V Hirsh, ...
Cancer 100 (12), 2613-2621, 2004
9282004
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the …
LS Rosen, D Gordon, S Tchekmedyian, R Yanagihara, V Hirsh, ...
Journal of Clinical Oncology 21 (16), 3150-3157, 2003
9102003
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma
TE Hutson, ID Davis, JPH Machiels, PL De Souza, S Rottey, B Hong, ...
Journal of Clinical Oncology 28 (3), 475-480, 2010
3542010
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ...
European urology 66 (5), 815-825, 2014
3502014
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
JP Dutcher, P de Souza, D McDermott, RA Figlin, A Berkenblit, A Thiele, ...
Medical oncology 26, 202-209, 2009
3352009
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized …
TK Choueiri, DJ Figueroa, AP Fay, S Signoretti, Y Liu, R Gagnon, K Deen, ...
Clinical Cancer Research 21 (5), 1071-1077, 2015
2752015
The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo‐controlled …
TH Diamond, J Winters, A Smith, P De Souza, JH Kersley, WJ Lynch, ...
Cancer 92 (6), 1444-1450, 2001
2152001
Markers of systemic inflammation predict survival in patients with advanced renal cell cancer
P Fox, M Hudson, C Brown, S Lord, V Gebski, P De Souza, CK Lee
British journal of cancer 109 (1), 147-153, 2013
1892013
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
CF Xu, NX Bing, HA Ball, D Rajagopalan, CN Sternberg, TE Hutson, ...
Journal of clinical oncology 29 (18), 2557-2564, 2011
1872011
Emerging roles for phospholipase A2 enzymes in cancer
KF Scott, M Sajinovic, J Hein, S Nixdorf, P Galettis, W Liauw, P de Souza, ...
Biochimie 92 (6), 601-610, 2010
1872010
Cancer-related fatigue in women with breast cancer: outcomes of a 5-year prospective cohort study
D Goldstein, BK Bennett, K Webber, F Boyle, PL De Souza, NRC Wilcken, ...
Journal of clinical oncology 30 (15), 1805-1812, 2012
1672012
Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer
W Scarano, P De Souza, MH Stenzel
Biomaterials science 3 (1), 163-174, 2015
1582015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results
MJ Morris, A Molina, EJ Small, JS De Bono, CJ Logothetis, K Fizazi, ...
Journal of Clinical Oncology 33 (12), 1356, 2015
1492015
Thiol–yne and thiol–ene “click” chemistry as a tool for a variety of platinum drug delivery carriers, from statistical copolymers to crosslinked micelles
VT Huynh, G Chen, P Souza, MH Stenzel
Biomacromolecules 12 (5), 1738-1751, 2011
1422011
Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer
AC Won, H Gurney, G Marx, P De Souza, MI Patel
BJU Int 112 (4), E250-E255, 2013
1352013
Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant …
CJ Ryan, MR Smith, JS De Bono, A Molina, C Logothetis, PL De Souza, ...
Journal of Clinical Oncology 30 (15_suppl), LBA4518-LBA4518, 2012
1352012
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20